SOURCE: Peregrine Pharmaceuticals

Peregrine Pharmaceuticals

April 13, 2010 09:00 ET

Peregrine Announces Data From Four Clinical Studies Will Be Presented at 2010 ASCO Annual Meeting

Will Include Data From Bavituximab Breast and Non-Small Cell Lung Cancer Phase II Studies and Cotara Brain Cancer Study

TUSTIN, CA--(Marketwire - April 13, 2010) -  Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM), a clinical stage biopharmaceutical company developing novel monoclonal antibodies for the treatment of cancer and viral infections, today announced that data from four clinical studies of bavituximab and Cotara® have been accepted for presentation at the 46th Annual Meeting of the American Society of Clinical Oncology (ASCO) to be held June 4-8, 2010 in Chicago, Illinois.

Abstracts Accepted at ASCO
Phase II study of bavituximab plus docetaxel in locally advanced or metastatic breast cancer (Abstract #1042)
Author: David Tabagari
Saturday, June 5, 2:00-6:00 PM

Phase II study of bavituximab plus paclitaxel and carboplatin in locally advanced or metastatic breast cancer: Interim results (Abstract #1062)
Author: Minish Jain
Saturday, June 5, 2:00-6:00 PM

Phase II study of bavituximab plus paclitaxel and carboplatin in untreated locally advanced or metastatic non-small cell lung cancer: Interim results (Abstract #7589)
Author: Raghunadharao Digumarti
Sunday, June 6, 8:00 AM - 12:00 PM

Open-label, dose confirmation, and dosimetry study of interstitial 131I-chTNT-1/B MAb for the treatment of recurrent glioblastoma multiforme (GBM): Final results (Abstract #2039)
Author: William R. Shapiro
Sunday, June 6, 8:00 AM - 12:00 PM

For more information on the ASCO conference, visit http://chicago2010.asco.org/Home.aspx.

About Peregrine Pharmaceuticals
Peregrine Pharmaceuticals, Inc. is a biopharmaceutical company with a portfolio of innovative monoclonal antibodies in clinical trials for the treatment of cancer and serious viral infections. The company is pursuing multiple clinical programs in cancer and hepatitis C virus infection with its lead product candidate bavituximab and novel brain cancer agent Cotara®. Peregrine also has in-house cGMP manufacturing capabilities through its wholly-owned subsidiary Avid Bioservices, Inc. (www.avidbio.com), which provides development and biomanufacturing services for both Peregrine and outside customers. Additional information about Peregrine can be found at www.peregrineinc.com.

Contact Information

  • Contacts:
    GendeLLindheim BioCom Partners
    Investors
    Email Contact
    (800) 987-8256

    Media
    Barbara Lindheim
    (212) 918-4650